At Fresh Tracks Therapeutics, our primary goal is to develop new molecules with potential first-in-class mechanisms that can disrupt current treatment paradigms and fundamentally improve the lives of patients suffering from debilitating immune-mediated conditions. We work toward achieving this goal by employing targeted, science-driven strategies that restore immune homeostasis within the body.
Restoring Immune Homeostasis
The immune system is a highly regulated and balanced system made up of two fundamental parts: the innate immune system and the adaptive immune system. These two systems work closely together, taking on different tasks to efficiently fight foreign substances in the body. However, imbalanced immune systems can result in a range of different autoimmune and inflammatory diseases.
Existing treatment regimens aim to suppress the overactive immune response, but more frequently come at very high costs for patients with autoimmune diseases, including life-impacting side effects. We believe now is the time to shift these very generalized approaches to a more targeted, science-driven therapy.
Our novel pipeline and next-generation platform consist of small molecule new chemical entities that potently and selectively modulate scientifically validated targets playing a driving role in well-defined immune-inflammatory diseases. We have access to both peripherally acting and brain penetrating molecules, which allow us to introduce potential therapies that may have an impact in restoring immune homeostasis in patients with autoimmune, inflammatory, neurodegenerative, and other high-impact diseases.
A potent, highly selective, and orally bioavailable potential first-in-class DYRK1A inhibitor with broad potential to treat debilitating autoimmune and inflammatory conditions
A novel, potent, and orally available covalent STING inhibitor with broad potential to treat autoinflammatory and rare monogenic diseases
Next-Generation Kinase Inhibitors
A cutting-edge platform of next-generation kinase inhibitors with the potential to produce treatments for autoimmune, neuroinflammatory, oncology, and other debilitating diseases
A potential first-in-class, topical DYRK1A inhibitor presenting an innovative approach to treat autoimmune dermatologic diseases